-
Innovation Ranking
NewInnovation Ranking – Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals Inc (Eiger), formerly known as Celladon Corp, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as lonafarnib and lambda which are used for the treatment of hepatitis delta virus infection; exendin 9-39 post-bariatric hypoglycemia; ubenimex for lymphedema and pulmonary arterial hypertension. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides...
-
Product Insights
NewNet Present Value Model: Eiger BioPharmaceuticals Inc’s Avexitide acetate
Empower your strategies with our Net Present Value Model: Eiger BioPharmaceuticals Inc's Avexitide acetate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Bristol-Myers Squibb Co’s Mezigdomide
Empower your strategies with our Net Present Value Model: Bristol-Myers Squibb Co's Mezigdomide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ivarmacitinib Sulfate in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivarmacitinib Sulfate in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivarmacitinib Sulfate in Alopecia Areata Drug Details: SHR-0302 (ARQ-250) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lonafarnib in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lonafarnib in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lonafarnib in Hepatitis D Drug Details: Lonafarnib (Zokinvy) is a synthetic tricyclic...
-
Product Insights
Hepatitis D – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis D - Drugs In Development, 2023’, provides an overview of the Hepatitis D pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Endocrine Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Endocrine Gland Disorders - Drugs In Development, 2023’, provides an overview of the Endocrine Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endocrine Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...